MariMed Inc. entered into a Restructuring and Exchange Agreement on February 24 2026, which was disclosed in a Form 8‑K filed on March 2 2026. The agreement replaces the February 28 2026 mandatory conversion of the company’s $14.725 million Series B Convertible Preferred Stock with a combination of long‑dated unsecured debt and a new equity component.
Under the new terms MariMed issued two promissory notes totaling $8 million: a $2 million note due March 1 2028 at 8% interest and a $6 million note due March 1 2031 at 10% interest. In addition, the company issued 26,900,000 shares of New Series B Convertible Preferred Stock with an aggregate liquidation preference of $6.725 million. The weighted‑average maturity of the obligation is extended by 4.6 years to 2031, significantly reducing near‑term refinancing risk.
The restructuring was driven by the original Series B guarantee that floor‑priced 4.9 million shares at $3.00 in 2020. With the market price around $0.10 at the time of the agreement, MariMed faced a substantial top‑up payment. By deferring that cash outflow and replacing the conversion deadline with debt and preferred equity, the company has strengthened its balance sheet and gained flexibility to invest in growth initiatives.
Financial context shows that in Q2 2025 MariMed reported revenue of $39.6 million, a 2% decline YoY, and a GAAP net loss of $1.3 million versus a $1.6 million loss in Q2 2024. Q3 2025 saw sequential increases in revenue, adjusted EBITDA, and operating cash flow, indicating that the company is managing its operations while the restructuring provides additional liquidity to support these trends.
CEO Jon Levine said, "By eliminating this 2026 obligation, we have strengthened our balance sheet and positioned the Company to focus on executing our growth initiatives." He added, "The obligation as restructured includes both unsecured debt at favorable market rates and an equity component with a conversion feature at a significant premium to current market."
Analysts had a moderate buy consensus, with one analyst setting a short‑term target of $0.25. While no immediate market reaction data is available, the restructuring is viewed as a positive step to reduce debt pressure in a low‑valuation cannabis market.
The deal reduces near‑term refinancing risk and defers a significant cash outflow, but it introduces potential dilution from the new preferred shares. MariMed remains a multi‑state cannabis operator focused on production and retail, facing industry headwinds such as pricing pressure and regulatory uncertainty. The restructuring positions the company to pursue growth while managing its capital structure in a challenging environment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.